J&J investment could be a tipping point for microbiome research

06/6/2013 | Forbes

Johnson & Johnson and Second Genome announced plans to collaborate on developing drugs that work on diseases such as ulcerative colitis by modifying intestinal bacteria. Second Genome, co-founded by former Pfizer innovation center president Corey Goodman, uses DNA sequencing to analyze organisms in a human stool sample, and then uses proprietary software to determine how drugs would affect the microbes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA